Vaidya Sane Ayurved Laboratories Ltd
MADHAVBAUG NSE
Vaidya Sane Ayurved Laboratories Ltd
HealthcareNSE: MADHAVBAUG Medical Equipment
Key Fundamentals
SMEMedical EquipmentHealthcareMarket Cap
₹173 Cr
Volatility
Low Risk
P/E Ratio
19.4
EBITDA
₹15.42 Cr
Return on Equity
11.44%
Debt to Equity
0.03
Book Value
₹83.16
52W High
₹335
52W Low
₹150
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vaidya Sane Ayurved Laboratories Ltd insights
47 extracted metrics + investor summaries across FY19–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Working capital days have increased from 41.3 days to 112 days
Growth Rate
Revenue Growth
16.59% ↗
Net Income Growth
20.97% ↗
Cash Flow Change
941.27% ↗
ROE
219.55% ↗
ROCE
185.07% ↗
EBITDA Margin (Avg.)
-15.76% ↗
Quarterly Results
| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 54 | 51 | 48 | 42 | 48 | 50 | 57 |
| Expenses | 41 | 50 | 48 | 46 | 36 | 40 | 41 | 50 |
| Operating Profit | 4 | 4 | 3 | 2 | 6 | 9 | 9 | 7 |
| OPM % | 9% | 7% | 5% | 3.8% | 14% | 18% | 17% | 12% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 |
| PBT | 4 | 3 | 2 | 1 | 5 | 5 | 6 | 4 |
| Tax % | 27% | 23% | 25% | 37% | 21% | 34% | 25% | 4% |
| Net Profit | 3 | 2 | 1 | 1 | 4 | 3 | 5 | 4 |
| EPS in Rs | 2.6 | 1.99 | 1.12 | 0.76 | 3.58 | 3.21 | 4.59 | 3.96 |
Profit & Loss
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 99 | 99 | 90 | 107 |
| Expenses | 91 | 95 | 76 | 91 |
| Operating Profit | 9 | 5 | 13 | 15 |
| OPM % | 9% | 4.5% | 15% | 14% |
| Other Income | 1 | 2 | 1 | 2 |
| Interest | 1 | 0 | 0 | 1 |
| Depreciation | 3 | 3 | 4 | 6 |
| PBT | 6 | 3 | 10 | 11 |
| Tax % | 25% | 30% | 28% | 17% |
| Net Profit | 5 | 2 | 7 | 9 |
| EPS in Rs | 4.59 | 1.88 | 6.8 | 8.55 |
| Div. Payout % | 5% | 0% | 0% | 0% |
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 |
| Reserves | 30 | 45 | 52 | 77 |
| Borrowings | 0 | 2 | 1 | 3 |
| Other Liabilities | 14 | 12 | 13 | 14 |
| Total Liabilities | 55 | 70 | 77 | 105 |
| Fixed Assets | 21 | 28 | 34 | 35 |
| CWIP | 2 | 2 | 1 | 2 |
| Investments | 15 | 18 | 21 | 40 |
| Other Assets | 17 | 21 | 20 | 28 |
| Total Assets | 55 | 70 | 77 | 105 |
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Operating | 0 | -1 | 11 | 5 |
| Investing | 1 | -13 | -10 | -24 |
| Financing | -1 | 15 | -1 | 17 |
| Net Cash Flow | -1 | 1 | 0 | -2 |
| Free Cash Flow | -7 | -12 | 2 | -2 |
| CFO/OP | 31 | -9 | 93 | 49 |
Ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 22 | 22 | 31 | 35 |
| Inventory Days | — | 58 | 82 | 70 |
| Days Payable | — | 101 | 149 | 127 |
| Cash Conversion Cycle | 22 | -20 | -37 | -21 |
| Working Capital Days | -2 | 5 | 7 | 112 |
| ROCE % | — | 6% | 18% | 15% |
Documents
1
Statement of deviation(s) or variation(s) under Reg. 32
18 Aug - Filed August 18, 2026 statement of deviation or variation in public issue fund utilisation. 18 Aug - Filed August 18, 2026 statement of deviation or variation in public issue fund utilisation.
2
Outcome of Board Meeting
24 Jul - Rohit Madhav Sane resigns as CEO on 23 July 2026; D. Ramakrishna appointed CEO from 24 July 2026. 24 Jul - Rohit Madhav Sane resigns as CEO on 23 July 2026; D. Ramakrishna appointed CEO from 24 July 2026.
3
Resignation of Director/KMP/SMP
24 Jul - Vaidya Sane Ayurved Laboratories Limited has informed about Resignation of Director/KMP/SMP 24 Jul - Vaidya Sane Ayurved Laboratories Limited has informed about Resignation of Director/KMP/SMP
4
Reply to Clarification- Financial results
20 Jul - Clarifies NSE query on FY26 financial results; revised XBRL filed, no impact on figures. 20 Jul - Clarifies NSE query on FY26 financial results; revised XBRL filed, no impact on figures.
5
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
16 Jul - Company confirms corporate governance provisions not applicable for quarter ended June 30, 2026 under SME exemption. 16 Jul - Company confirms corporate governance provisions not applicable for quarter ended June 30, 2026 under SME exemption.
Frequently Asked Questions about Vaidya Sane Ayurved Laboratories Ltd
What does Vaidya Sane Ayurved Laboratories Ltd do?
Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running
of hospitals & clinics, and sale of Ayurved based medicines[1]
Where is Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) listed?
Vaidya Sane Ayurved Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: MADHAVBAUG. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Vaidya Sane Ayurved Laboratories Ltd belong to?
Vaidya Sane Ayurved Laboratories Ltd operates in the Healthcare sector within the Medical Equipment industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Vaidya Sane Ayurved Laboratories Ltd?
Vaidya Sane Ayurved Laboratories Ltd has a market capitalisation of approximately ₹173.47 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Vaidya Sane Ayurved Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Vaidya Sane Ayurved Laboratories Ltd is 19.40. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Vaidya Sane Ayurved Laboratories Ltd?
Over the past 52 weeks, Vaidya Sane Ayurved Laboratories Ltd has traded between a low of ₹150 and a high of ₹335. This range helps investors understand the stock's price volatility and recent trading levels.
Does Vaidya Sane Ayurved Laboratories Ltd pay dividends?
Yes, Vaidya Sane Ayurved Laboratories Ltd has a dividend yield of 0.30%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Vaidya Sane Ayurved Laboratories Ltd?
Vaidya Sane Ayurved Laboratories Ltd has a Return on Equity (ROE) of 11.44%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Vaidya Sane Ayurved Laboratories Ltd on Tapetide?
On Tapetide, you can view Vaidya Sane Ayurved Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running of hospitals & clinics, and sale of Ayurved based medicines[1]